ArticleACS pharmacology & translational science2025
Catalytic Site Inhibitors of Group 1 Allergens Prevent Toll-like Receptor (TLR)4- and TLR1/2-Dependent Innate Responses in Keratinocytes and Airway Epithelial Cells Exposed to House Dust Mite Allergenic Extract.
Article in ACS pharmacology & translational science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dysregulated immune responses to domestic allergens are underlying events in atopic dermatitis (AD), an inflammatory disease of humans and domestic companion animals characterized by itching and eczema. The house dust mite (HDM) allergome, notably the cysteine protease group 1 allergens, is an important trigger of AD. This protease activity is implicated in innate mechanisms which both initiate and reinforce allergic sensitization, prompting interest in the design of protease inhibitors as a novel allergy therapy. We examined pyruvamide chemotype protease inhibitors on intracellular reactive oxidant species (ROS) production induced by HDM allergen extracts in HaCaT keratinocytes and identified promising topical and orally bioavailable candidates. We then explored the wider signaling network affected by this allergen inhibition in keratinocytes and airway epithelial cells (AECs). Optimized pyruvamides with different properties (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.